	US 11,851,440 B2
	Modulators of eukaryotic initiation factor 2B, compositions and methods
Robert A. Craig, II, South San Francisco, CA (US); Javier de Vicente Fidalgo, Foster City, CA (US); Anthony A. Estrada, Danville, CA (US); Jianwen A. Feng, San Mateo, CA (US); Brian M. Fox, Redwood City, CA (US); Christopher R. H. Hale, South San Francisco, CA (US); Katrina W. Lexa, San Francisco, CA (US); Maksim Osipov, Redwood City, CA (US); Travis Remarchuk, South San Francisco, CA (US); and Zachary K. Sweeney, Redwood City, CA (US)
Assigned to Denali Therapeutics Inc., South San Francisco, CA (US)
Filed by Denali Therapeutics Inc., South San Francisco, CA (US)
Filed on Nov. 19, 2021, as Appl. No. 17/531,039.
Application 17/531,039 is a continuation of application No. 16/637,718, granted, now 11,236,100, previously published as PCT/US2018/045868, filed on Aug. 8, 2018.
Claims priority of provisional application 62/608,504, filed on Dec. 20, 2017.
Claims priority of provisional application 62/553,728, filed on Sep. 1, 2017.
Claims priority of provisional application 62/543,307, filed on Aug. 9, 2017.
Prior Publication US 2022/0411433 A1, Dec. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4245 (2006.01); A61K 31/4164 (2006.01); A61K 31/415 (2006.01); A61K 31/421 (2006.01); C07D 491/048 (2006.01); C07C 235/22 (2006.01); C07D 207/27 (2006.01); C07D 233/36 (2006.01); C07D 233/42 (2006.01); C07D 233/61 (2006.01); C07D 233/64 (2006.01); C07D 249/04 (2006.01); C07D 249/08 (2006.01); C07D 257/04 (2006.01); C07D 261/04 (2006.01); C07D 261/08 (2006.01); C07D 263/32 (2006.01); C07D 263/38 (2006.01); C07D 263/56 (2006.01); C07D 271/06 (2006.01); C07D 271/10 (2006.01); C07D 291/04 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 413/04 (2006.01); C07D 413/06 (2006.01); C07D 413/12 (2006.01); C07D 417/04 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)

CPC C07D 491/048 (2013.01) [A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/421 (2013.01); A61K 31/4245 (2013.01); C07C 235/22 (2013.01); C07D 207/27 (2013.01); C07D 233/36 (2013.01); C07D 233/42 (2013.01); C07D 233/61 (2013.01); C07D 233/64 (2013.01); C07D 249/04 (2013.01); C07D 249/08 (2013.01); C07D 257/04 (2013.01); C07D 261/04 (2013.01); C07D 261/08 (2013.01); C07D 263/32 (2013.01); C07D 263/38 (2013.01); C07D 263/56 (2013.01); C07D 271/06 (2013.01); C07D 271/10 (2013.01); C07D 291/04 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01)]

18 Claims

1. A method for treating a disease or condition mediated, at least in part, by eukaryotic initiation factor 2B, the method comprising administering to a subject in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, selected from the group consisting of: